Abstract. In this paper, we propose an iterating principle in the bootstrap method to assess the individual bioequivalence under 2 4 randomized crossover design. The …nite sample properties of the proposed algorithm are illustrated by an extensive simulation study and a real-world example. Our …ndings reveal that the proposed idea have better performance than the classical percentile bootstrap con…dence limits.
Introduction
Bioequivalence (BE) studies play an important role in the drug development process. The goal of such studies is to evaluate the therapeutic equivalence of two (or more) drugs or to study if two di¤erent galenic formulations of the same drug have a similar bioavailability and therapeutic e¤ect. Let T be a generic drug developed as an alternative to a reference drug (R). The United States Food and Drug Administration (FDA) requires BE before marketing formulation T or new formulations of the existing drugs. A formal de…nition of the BE given by [4] is as follows: "Bioequivalence is de…ned as the absence of a signi…cant di¤erence in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study." Usually, the BE studies are carried out by measuring the drug concentration in the blood by several pharmacokinetic variables. The commonly used pharmacokinetic variables are the area under the plasma concentration curve (AUC ), the maximum drug concentration (C max ) and the time required to reach the maximum drug concentration (T max ). Note that the BE studies are performed with healthy volunteer subjects.
There are three types of BE: (i) The average bioequivalence (ABE), which compares the distance of average pharmacokinetic measures between the formulations 584 
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T and R; (ii) The population bioequivalence (PE), which compares the population means under the test and reference formulation as well as the between-subject variance in bioavailability; (iii) The individual bioequivalence (IBE), which additionally takes into account the subject-by-formulation interaction for the test and reference formulation. This paper aims to contribute to the IBE studies by resampling procedures. For more information about the types of BE studies please see [7] .
Generally, a two sequence-four period (2 4) randomized crossover design is recommended to assess the IBE. A crossover design is a repeated measurements design so that the experimental units cross over from one treatment to another during the di¤erent time periods. Such design has formed the basis of the many clinical studies, see [15] and [8] for more information about the crossover designs in medical studies. Note that, as pointed out by referee, this design can be used properly in drug studies when the drugs under consideration are used only for symptomatic purposes not for the treatment. For analyzing the IBE, aggregate, scaled and moment based measures, which are nonlinear functions of the di¤erence of the means (T -R) and the various variance components, are proposed by [12] , [13] and [14] . [3] proposes using the upper limit of a 90% con…dence interval to test the hypothesis of IBE. However, it is di¢ cult to determine the exact distribution of the estimators calculated for the measures mentioned above since they have a nonlinear form. To overcome this problem [12] suggests to use the original nonparametric bootstrap method to build up a con…dence interval for the statistics since it does not require the full knowledge of the underlying data and distributional assumptions. [16] proposes an improved procedure to assess the IBE and [10] reviews the di¤erent concepts of IBE by concentrating on the bootstrap percentile interval. See also [11] and references therein for the history of IBE and the role of the bootstrap in this context.
The theoretical properties such as consistency and accuracy of the recommended bootstrap percentile intervals to test the IBE hypothesis are discussed by [16] . The authors conclude that the FDA's bootstrap procedure using the moment-based approach yields a consistent test procedure. On the other hand, the iterated bootstrap method (see, [5] ) can be useful in obtaining an arbitrarily high degree of correction and improving the e¢ ciency of bootstrap by iterating the bootstrap argument. [5] , [1] , [2] and [6] provide theoretical properties of this method and prove that the iterating principle reduces the bootstrap errors in many statistical problems. This paper proposes the use of iterated bootstrap algorithm with an aim to reduce the coverage error of the percentile con…dence interval in individual bioequivalence studies.
The rest of the paper is organized as follows. In Section 2 we provide a detailed information on the IBE and bootstrap methods examined in this study. An extensive Monte Carlo simulation is conducted to examine the …nite sample performance of the iterated bootstrap method and the results are presented in Section 3. Section 4 presents the numerical results for the real-world example considered in this study. Finally, we conclude with some …nal remarks described in Section 5.
Methodology
A two sequence-four period randomized crossover design T RT R and RT RT is commonly recommended for assessing IBE. Under this design, four drug treatments in the order of T RT R are administrated to the …rst sequence of n 1 patients whereas in the second sequence, the treatments are administrated in the order of RT RT to n 2 patients. Let Y ijk represents the log transformed response (i.e., Y = log AU C or log C max ) for subject i in the jth period of sequence k, where i = 1;
; n k , j = 1; 2; 3; 4 and k = 1; 2. The following mixed-e¤ect model is recommended:
where is the overall mean, P j is the …xed e¤ect of the jth period (j = 1; 2; 3; 4 and P 1 + P 2 + P 3 + P 4 = 0), Q k is the …xed e¤ect of the kth sequence (k = 1; 2 and Q 1 + Q 2 = 0), F l is the …xed e¤ect of the lth drug formulation (l = T when (k,j) = (1,1), (1,3), (2,2), (2,4) and l = R otherwise, F t + F r = 0), W ljk is the …xed e¤ect of interaction (sum of W ljk 's over any index is 0), S ikl is the random e¤ect of the ith subject in the kth sequence under drug formulation l and (S ikT , S ikR ), i = 1; ; n k , k = 1; 2 are independent and identically distributed random vectors with mean 0 and unknown covariance matrix
ijk 's are independent random errors with mean 0 and variance 2 W l , and (S ikT , S ikR )'s and ijk 's are independent (for more information please see [16] ). Note that: (i) (ii) The correlation between the test and reference formulations responses from subject i, , is related to the subject-by-formulation interaction variance Table 1 shows the expected means and observed data of the crossover design considered in this study. 
; n 1 i = 1;
; n 2 i = 1; 
3)
2 is the variance calculated under the reference formulation, U is the predetermined upper limit for IBE, and 
where
.1 is …tted by using general linear models, maximum likelihood or restricted maximum likelihood (REML) procedures. FDA recommends the use of REML method to estimate the mean di¤erence and variance components. REML uses an iterative process where each iteration has two steps. In the …rst step it uses the initial parameter estimates to estimate the …xed e¤ects. Then, in the second step, the variance parameters are re-estimated by using the residuals obtained from the …rst step. These two steps are repeated when the parameter estimates do not change from one iteration to the next. It has two main properties; it is useful to estimate between and within subject variances, and it may be useful to estimate the mean di¤erences and variance components when the data set is incomplete. Also, [17] shows that the bootstrap procedure using REML yields a consistent test procedure. On the other hand, as described by [16] , it may not produce the best estimator of and may not be robust against the violation of the normality assumption. Also, it requires a large amount of computation time since REML estimators involves an iteration process. The moment method which is simple and robust against the normality assumption can be used to estimate the mean di¤erence and variance components as an alternative to the method of REML. Following [16] 
; n 1
; n 2 and let z jk and s 2 jk be the sample mean and sample variance based on z 1jk ; ; z n k jk , for each …xed (j; k). Then, the unbiased estimators of F T F R , and 
Step 1. Estimate the IBE parameter
Step 2. Let Y i1 = (y iT 11 ; y iR11 ; y iT 12 ; y iR12 ) and Y i2 = (y iR21 ; y iT 21 ; y iR22 ; y ; Y n22 )g with replacement from Y 1;2 . Note that, the bootstrap resampling is strati…ed by sequence.
Step 3. Calculate the bootstrap estimate of^ ,^ , by using the bootstrap data set
Step 4. Repeat steps 2 and 3 B times.
Step 5. Determine the 95th percentile (^ F DA (95)) of this generated bootstrap distribution.
Step 6.^ F DA (95) is then compared to U to conclude that two formulations are bioequivalent or not.
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[16] studies the properties of this test procedure and they conclude that the bootstrap procedure in the FDA's draft guidance is incorrect. The authors suggest to use the bootstrap estimate^ as in Equation 2.7 given below.
The 95th percentile calculated by using this bootstrap estimate is called the bootstrap percentile (BP) upper con…dence bound for ,^ BP (95). The use of iterated bootstrap procedure mentioned in Section 1 may provide better upper con…dence bounds since it improves the coverage accuracy of bootstrap percentile con…dence intervals. Let X 1 ; X 2 ; be a sequence of i.i.d. random variables from an unknown distribution F F , where the parameter is of our primary interest. Let n = (X 1 ; ; X n ) be an i.i.d. random sample from F , and let R n ( n ; ) be the pivotal quantity whose distribution is given by G n = G n ( ; F ). Suppose is the set of all possible values of . Then, a level con…dence set for the parameter can be obtained as
for any given 2 (0; 1), where G 1 n ( ) describes the largest -th quantile of G n . For any sequence fF n g which converges to F , G n ( ; F n ) is supposed to converge weakly to a continuous distribution function G = G( ; F ). Then, G n (R n ( n ; )) is distributed as uniform U (0; 1). In classical theory, G n is approximated by its limit. However, in most cases, it is not easy to obtain its limit when the estimate of the parameter is a complicated statistic. But bootstrap method makes it possible since it does not require the full knowledge of the underlying distribution. Let n = (X 1 ; ; X n ) be the bootstrap sample from F n , where F n is the empirical distribution function which puts mass 1=n to each data point. Let also b be the estimate of based on n . Then, the bootstrap analogue of R n ( n ; ) with the bootstrap distribution conditional on n are given as R n = R n ( n ; b ) and G n = G n ( ; F n ), respectively. Similar to the Equation 2.8, the bootstrap estimate of S n is obtained as S n = ft 2 : R n ( n ; t) G 1 n ( )g Since F n is a consistent estimate for F , the bootstrap estimate G n converges in probability to G as n increases. Moreover, G n (R n ( n ; b )) converges to a uniform U (0; 1) distribution.
For the …nite samples, the level of the con…dence set given above tends to be inaccurate. One way of improving it is to use the iterating principle which is based on [1] 's prepivoting idea such that it transforms the original root R n ( n ; ) into a new root R n;1 ( n ; ) = G n fR n ( n ; )g whose distribution is less dependent to F compared to R n . In other words, mapping R n into R n;1 is called prepivoting. Note that R n;1 ( n ; ) is exactly distributed U (0; 1) if R n ( n ; ) is the pivot. Let G n;1 (x) = P(R n;1 ( n ; ) x) be the distribution of R n;1 ( n ; ), and let G n;1 (x) = P(R n;1 ( n ; b ) xj n ) be its bootstrap estimate. Then S n;1 = ft 2 : R n;1 ( n ; ) G
de…nes level iterated bootstrap con…dence set for . Generally, the error in S n;1 is smaller than the error in S n and S n . The iteration can be repeated continuously to reduce the coverage error of a con…dence interval to a desired level. On the other hand, each iteration increases the computation burden drastically. [9] shows that each iteration reduces the coverage error by an order of n 1=2 and n 1 for one-sided and two-sided intervals, respectively. By considering the computational burden of this iterative procedure, to make our proposed method more practical and widely applicable we only recommend of doing the double bootstrap where iteration is only being done once.
The iterated bootstrap algorithm used in this study works as follows: First, drawn a simple random sample of size n k with replacement from Y 1;2 . For the second level bootstrap, drawn another simple random sample of size n k with replacement from P B2 j=1 I(R n;j R n;i ) for i = 1; ; B 1 .
(d) Then, the empirical cumulative distribution of Z i 's, G n is asymptotically U (0; 1), and approximate the distribution of R n , G n = P(R (Y 1;2 ; b ) ).
(e) De…ne the level con…dence set of iterated bootstrap for R n as S n = f :
Then the iterated versions of the bootstrap upper con…dence limits,^ F DA (95) and^ BP (95), for assessing IBE hypothesis can easily be obtained by using the algorithm given above. 
Numerical Results
To investigate the performances of the iterated bootstrap con…dence limits we carried out a simulation study under di¤erent parameter settings and sample sizes, and we compared our results with classical percentile bootstrap con…dence limits by means of estimated test size ( ) and power of the test ( ). The parameter settings (where H 0 in Equation 2.3 hold) presented in Table 2 were considered to calculate the values, and the parameter settings (where H 1 in 2.3 is actually true) in Table  3 were considered to calculate the values. 2 4 randomized crossover design was considered to assess the IBE. For each simulated experiment, four drug treatments were arranged in the order of T RT R in sequence 1 whereas the treatment order was arranged as RT RT in sequence 2. For each parameter setting, 100 experiments were simulated, and for each case, a sample of size n was generated, and B 1 = B 2 = 2000 bootstrap resamples were generated in each resampling operation. The boundary of the null hypothesis of individual bioequivalence ( U ) and the within subject variances for the reference formulation ( Table 4 .
Our …ndings show that, for all sample sizes and parameter settings under considered, iterated bootstrap methods outperform their conventional counterparts in terms of power values. The estimated test sizes of the conventional bootstrap methods (^ F DA (95) and^ BP (95)) are smaller than the nominal size = 0:05, in general. For the iterated bootstrap methods (^ F DA (95) and^ BP (95)), the test sizes are larger than the nominal size under …rst parameter setting. On the other hand, for the other parameter settings, they tend to have a reasonable test sizes, which are close to the nominal size = 0:05, but still larger than the ones obtained by the conventional methods. It is not a surprising result since a large test size corresponds to a large power of the test. 
A real-world example
In this section, we studied the performances of the iterated and traditional bootstrap methods for assessing IBE by a real-world example. For this purpose, we used a dataset given by the FDA: The antihypertensive patch dataset (see Table 5 ) which is consisted of a total of 37 subjects. For this dataset, an antihypertensive patch were administered to the …rst sequence of 18 patients in the order of T RRT, and in the second sequence, the treatments were administrated in the order of RT T R to 19 patients. This dataset have a large subject-by-formulation interaction ( D > 0: 15) , and hence it is necessary to test the IBE. We used logarithmically transformed AU C and C max datasets to test the IBE. Both classical and iterated bootstrap methods were used to constructed upper limit of 95% con…dence interval for IBE and the results are presented in Table 6 .
The dataset given in Table 5 is analyzed using the REML method by [7] and based on their results they state that: (i) ABE can be concluded based on the values obtained for AU C, but the C max data fail, (ii) PBE can be concluded in either case, i.e., based on the AU C and on the C max data, and (iii) IBE cannot be concluded in either case. This may be due to a high subject-by-formulation interaction that seems to be present in this dataset, as pointed out by the FDA. According to our results (see Table 6 ) IBE can be concluded for C max dataset but the IBE test is rejected for AU C dataset (since the upper limits of 95% CI calculated for this dataset are greater than the boundary of the null hypothesis speci…ed by the FDA) when^ F DA (95) and^ BP (95) are used. On the other hand, IBE can be concluded in either case when the iterated bootstrap upper con…dence limits (^ F DA (95) and^ BP (95)) are used.
Conclusion
In this study, we propose to use iterated bootstrap algorithm to test the individual bioequivalence hypothesis under 2 4 randomized crossover design, and we compare their performances with the conventional bootstrap methods both by simulations and a case study. The important result produced by iterated bootstrap algorithm is that the power of the test obtained by this method are signi…cantly better than those obtained by classical bootstrap methods. Hence, this paper shows that more reliable results can be obtained by using iterated bootstrap method to assess the individual bioequivalence. On the other hand, the proposed iteration in ‡ates the type I error rate to approximately 20% (but have more power than the traditional bootstrap) when the parameter is close to the boundary of the null hypothesis of individual bioequivalence U (as in the …rst parameter setting (see 2)) and the sample size is small. Such high type I error rate may not be acceptable in drug studies since high type I error increases the chance of rejecting the null hypothesis when it is actually true. In this case, the number of iterations and/or bootstrap replicates B can be increased to decrease the type I error rate. As a …nal comment, it should be noted that the iterated bootstrap requires much more computational cost than the traditional bootstrap. For example, while the bootstrap runs only for B resamples in a simulation iterated bootstrap requires B 2 + B resamples in the …rst iteration (double bootstrap), B 3 + B 2 + B resamples in the second iteration, and so on. However, it is worth trying iteration considering its performance and the increasing technology. 
